title: Epigenetic biomarkers associated with antitumour necrosis factor drug response in moderate-to-severe psoriasis.
authors.affiliation: Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, Spain.
authors.forename: M C
authors.identifier: 0000-0003-4082-5165
authors.initials: MC
authors.lastname: Ovejero-Benito
authors.affiliation: Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, Spain.
authors.forename: T
authors.initials: T
authors.lastname: Cabaleiro
authors.affiliation: Clinical Neurophysiology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, Spain.
authors.forename: A
authors.identifier: 0000-0002-5024-5108
authors.initials: A
authors.lastname: Sanz-García
authors.affiliation: Dermatology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, Spain.
authors.forename: M
authors.identifier: 0000-0002-1187-1341
authors.initials: M
authors.lastname: Llamas-Velasco
authors.affiliation: Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, Spain.
authors.forename: M
authors.identifier: 0000-0002-1660-3135
authors.initials: M
authors.lastname: Saiz-Rodríguez
authors.affiliation: Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Prieto-Pérez
authors.affiliation: Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Talegón
authors.affiliation: Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Román
authors.affiliation: Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, Spain.
authors.forename: D
authors.initials: D
authors.lastname: Ochoa
authors.affiliation: Dermatology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Reolid
authors.affiliation: Dermatology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, Spain.
authors.forename: E
authors.identifier: 0000-0002-0676-1260
authors.initials: E
authors.lastname: Daudén
authors.affiliation: Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, Spain.|Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
authors.forename: F
authors.identifier: 0000-0002-6519-8885
authors.initials: F
authors.lastname: Abad-Santos
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D003879:Dermatologic Agents / Q000627:therapeutic use*; D044127:Epigenesis, Genetic / Q000502:physiology; D000068800:Etanercept / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D015415:Biomarkers; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept